M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

76 deals · US$92bndisclosed · Pharma · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Jun 2025 Felix Pharmaceuticals Pvt –Advent InternationalStakeAnnounced–Animal Health+2 A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side)
Jul 2025 Altanine –Polomar Health ServicesMergerPending–Healthcare+1
Sep 2025 Zentiva Advent InternationalGTCRAcquisitionAnnounced–Pharma+1 Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Dec 2025 MindWave Innovations –Apimeds Pharmaceuticals USMergerCompleted–Biotech+1 Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side)
Dec 2025 Amicus Therapeutics –BioMarinAcquisitionAnnounced4,800.0Biotech+2 Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side)
Dec 2025 Dynavax Technologies –SanofiAcquisitionAnnounced2,200.0Biotech+1 Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side)
2026 Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) –ACS DobfarAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Lincoln International (sell-side)
2026 Egetis –ANI PharmaceuticalsAcquisitionAnnounced560.0Pharma+1 Centerview Partners (sell-side)
Jan 2026 Biogaran ServierBC PartnersAcquisitionAnnounced–Pharma Lazard
Jan 2026 Wonderbelly –Procter & GambleAcquisitionCompleted–Consumer Health+1 Perella Weinberg Partners (sell-side)
Jan 2026 Lantheus SPECT business LantheusSHINE TechnologiesAsset saleAnnounced–Pharma+2 Solomon Partners (sell-side)
Jan 2026 Nivagen Pharmaceuticals –PAI PharmaAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side)
Jan 2026 PTC Therapeutics' remaining royalty on Roche's Evrysdi PTC TherapeuticsRoyalty PharmaAsset saleAnnounced240.0Specialty finance and leasing+2 Goodwin (buy-side)
Jan 2026 Ventyx Biosciences –Eli Lilly and CompanyAcquisitionAnnounced1,200.0Biotech+2 Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side)
Jan 2026 Radius Health Patient Square CapitalB-FLEXION Life SciencesAcquisitionAnnounced–Pharma Kirkland & Ellis (sell-side)Centerview Partners (sell-side)
Jan 2026 TerSera Infusion Specialty Therapies Business Unit (IST) TerSera TherapeuticsESTEVEAsset salePending–Pharma Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side)
Feb 2026 Apex Healthcare Berhad –Quadria Capital-led consortiumAcquisitionAnnounced–Pharma+1 Latham & Watkins (buy-side)
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionAnnounced2,400.0Biotech+1 Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side)
Feb 2026 Avadel Pharmaceuticals –AlkermesSchemeCompleted–Pharma+1 Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side)
Feb 2026 AiCuris Anti-infective Cures AG –Veloxis PharmaceuticalsAcquisitionAnnounced913.0Pharma+1 Gibson Dunn (sell-side)Freshfields (buy-side)
Mar 2026 Transcend Therapeutics –OtsukaAcquisitionAnnounced700.0Biotech+2 Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side)
Mar 2026 Paratek Pharmaceuticals ––MergerCompleted–Pharma Skadden, Arps, Slate, Meagher & Flom
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
Mar 2026 Corstasis Therapeutics –Esperion TherapeuticsAcquisitionCompleted75.0Pharma+1 PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side)
Mar 2026 Novartis India Novartis AGWaveRise InvestmentsAcquisitionAnnounced–Pharma Freshfields (sell-side)
Mar 2026 Day One Biopharmaceuticals –ServierAcquisitionPending2,500.0Biotech+2 Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side)
Mar 2026 AZSTARYS business Corium Therapeutics HoldingsCollegium PharmaceuticalAsset salePending650.0Pharma Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side)
Mar 2026 AnaptysBio outstanding common stock –AnaptysBioBuy-backAnnounced100.0Biotech+1 Piper Sandler (buy-side)
Mar 2026 Kezar Life Sciences –Aurinia PharmaceuticalsAcquisitionAnnounced51.5Biotech+1 TD Securities (sell-side)Cooley (sell-side)
Mar 2026 Apellis Pharmaceuticals –BiogenAcquisitionAnnounced5,600.0Biotech+2 Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side)
Mar 2026 Centessa Pharmaceuticals –Eli Lilly and CompanySchemePending6,300.0Biotech+1 Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Apr 2026 Cumberland U.S. branded businesses Cumberland PharmaceuticalsApotexAsset saleAnnounced–Pharma Kirkland & Ellis (buy-side)
Apr 2026 Modeyso commercial sales royalties Former Oncoceutics Inc. securityholdersHealthCare RoyaltyAsset saleAnnounced–Specialty finance and leasing+3 Latham & Watkins (sell-side)
Apr 2026 Exclusive global rights to TAK-063 (balipodect) Takeda Pharmaceutical Co.Axsome TherapeuticsAsset saleCompleted–Pharma+1 Sidley Austin (buy-side)
Apr 2026 Soleno Therapeutics –Neurocrine BiosciencesAcquisitionCompleted2,900.0Biotech+2 Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side)
Apr 2026 Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) Assertio HoldingsCosette PharmaceuticalsAsset saleCompleted35.0Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)
Apr 2026 Worldwide rights to Kenalog Bristol-Myers SquibbSubsidiary of Piramal PharmaAsset saleAnnounced35.0Pharma Goodwin (buy-side)
Apr 2026 Assertio Holdings –Zydus Worldwide DMCCAcquisitionAnnounced166.4Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side)
Apr 2026 US sales and distribution rights for seven Assertio branded products Assertio HoldingsCosette PharmaceuticalsAsset saleAnnounced–Pharma Gibson Dunn (sell-side)
Apr 2026 Neurona Therapeutics –UCBAcquisitionAnnounced650.0Biotech+2 Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side)
Apr 2026 Kashiv BioSciences –Amneal PharmaceuticalsAcquisitionCompleted375.0Biotech+2 J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side)
Apr 2026 Cumberland FDA-approved commercial products and related assets Cumberland PharmaceuticalsNuvo Pharmaceuticals (Ireland) DACAsset salePending100.0Pharma VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side)
Apr 2026 Organon & Co. –Sun Pharmaceutical IndustriesAcquisitionAnnounced11,750.0Pharma Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side)
Apr 2026 KalVista Pharmaceuticals –Chiesi GroupAcquisitionCompleted1,900.0Pharma+2 Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side)
Apr 2026 Shionogi-Apnimed Sleep Science ApnimedShionogi & Co.AcquisitionAnnounced100.0Pharma+1 Goodwin (sell-side)
Apr 2026 Emalex Biosciences –Teva PharmaceuticalsAcquisitionAnnounced700.0Pharma+1 Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side)
May 2026 CVC and GBL-led Recordati acquisition consortium –CPP InvestmentsStakeAnnounced–Pharma Kirkland & Ellis (buy-side)
May 2026 Recordati S.p.A. –CVC GBLAcquisitionAnnounced12,516.9Pharma Latham & Watkins (buy-side)Jefferies (buy-side)
May 2026 Esperion Therapeutics –ARCHIMEDAcquisitionPending1,100.0Pharma+1 Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side)
May 2026 Catalyst Pharmaceuticals –Angelini Pharma S.p.A.AcquisitionPending4,100.0Pharma+1 J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.